Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SBLOF'
s EV-to-EBIT Range Over the Past 10 Years
Min: -5600.34 Med: 11.88 Max: 53.24
Current: 11.65
During the past 13 years, the highest EV-to-EBIT of Shin Nippon Biomedical Laboratories was 53.24. The lowest was -5600.34. And the median was 11.88.
SBLOF's EV-to-EBIT is ranked better than 75.96% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.585
vs SBLOF: 11.65
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Shin Nippon Biomedical Laboratories's Enterprise Value for the quarter that ended in Mar. 2026 was $526.9 Mil.
Shin Nippon Biomedical Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $42.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories EV-to-EBIT Related Terms
Shin Nippon Biomedical Laboratories EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shin Nippon Biomedical Laboratories EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Shin Nippon Biomedical Laboratories's EV-to-EBIT falls into.
Shin Nippon Biomedical Laboratories's current Enterprise Value is $478.8 Mil.
Shin Nippon Biomedical Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $42.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories (SBLOF) has a EV-to-EBIT of 11.37 as of Jul. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shin Nippon Biomedical Laboratories and its competitors. This is near median its historical median of 11.88. According to the industry distribution chart, Shin Nippon Biomedical Laboratories ranks #25 out of 104 companies in the Medical Diagnostics & Research industry, placing it in the top 24%.
Is Shin Nippon Biomedical Laboratories' EV-to-EBIT too high?
Shin Nippon Biomedical Laboratories' current EV-to-EBIT of 11.37 is near median its 10-year median of 11.88. The Medical Diagnostics & Research industry median EV-to-EBIT is 22.59. Shin Nippon Biomedical Laboratories' value of 11.37 is 49.7% below this industry median. Based on the distribution chart, Shin Nippon Biomedical Laboratories ranks #25 out of 104 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shin Nippon Biomedical Laboratories ranks #25 out of 104 companies for EV-to-EBIT. This places Shin Nippon Biomedical Laboratories in the top 24% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 22.59. Shin Nippon Biomedical Laboratories' value of 11.37 is 49.7% below this benchmark. While the company's 10-year median is 11.88 vs. the industry median of 22.59, Shin Nippon Biomedical Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.59, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shin Nippon Biomedical Laboratories's current EV-to-EBIT of 11.37 is 49.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shin Nippon Biomedical Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shin Nippon Biomedical Laboratories's current EV-to-EBIT is 11.37, which is near median its own 10-year median of 11.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current EV-to-EBIT of 11.37. The stock's GF Value™ is $12.76, compared to a current price of $9.16 — trading 28.2% below its estimated fair value. The current EV-to-EBIT is 11.37, which is near median its 10-year median of 11.88 and 49.7% below the Medical Diagnostics & Research industry median of 22.59. Shin Nippon Biomedical Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current EV-to-EBIT is 11.37 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?
Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued.
The current stock price of $9.16 is trading 28.2% below its estimated GF Value™ of $12.76.
Key valuation signals for SBLOF:
EV-to-EBIT: 11.37 (near median its 10-year median of 11.88)
GF Value™: $12.76 vs. price of $9.16 (28.2% below fair value)
Industry Position: 49.7% below the Medical Diagnostics & Research median (#25 of 104)
No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shin Nippon Biomedical Laboratories Business Description
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
74GF Score
Get the complete analysis for SBLOF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBLOF has been successfully added to your 
